文献速递胸部肿瘤

KEYNOTE-867:立体定向放疗联合帕博利珠单抗治疗不可手术I/II期NSCLC的III期随机双盲研究

KEYNOTE-867: A Phase III, Randomized, Double-Blind Study of Stereotactic Body Radiotherapy With Pembrolizumab for Unresected Stage I or II Non-Small Cell Lung Cancer.
PubMed 文献 · J Clin Oncol · 2026-10-28

KEYNOTE-867研究纳入448例不可手术或拒绝手术的I/II期NSCLC患者,随机接受SBRT联合帕博利珠单抗或安慰剂。

要点

  • SBRT联合帕博利珠单抗未改善I/II期不可手术NSCLC的EFS。
  • 联合组3-5级治疗相关不良事件发生率20.4%,高于安慰剂组的3.7%。
  • 联合组发生5例治疗相关死亡(2.2%),安慰剂组无治疗相关死亡。

核心结论

  • 在不可手术的I/II期NSCLC中,SBRT联合帕博利珠单抗较SBRT联合安慰剂未改善EFS,且治疗相关不良事件发生率更高。
  • 基于风险获益比,KEYNOTE-867试验提前终止,所有研究治疗停止。

研究设计与样本

  • III期随机双盲研究,纳入448例未经治疗、不可手术或拒绝手术的I/II期(T1至局限T3,N0,M0,AJCC第8版)NSCLC成人患者。
  • 患者1:1随机接受胸部SBRT(原发肿瘤,≤2周)联合帕博利珠单抗200 mg或安慰剂,每3周一次,≤17个周期。
  • 主要终点为盲法独立中心审查评估的无事件生存期(EFS)。

主要发现

  • 在至少接受一剂研究治疗的患者中,帕博利珠单抗组46/226(20.4%)发生3-5级治疗相关不良事件,安慰剂组8/218(3.7%)。
  • 帕博利珠单抗组发生5例治疗相关死亡(2.2%),安慰剂组无治疗相关死亡。

临床怎么用

  • 不推荐在不可手术I/II期NSCLC中常规将帕博利珠单抗联合SBRT用于临床实践。
  • SBRT仍是不可手术I/II期NSCLC的标准治疗。

局限性

  • 研究因风险获益比不佳提前终止,可能影响长期疗效评估。
  • 中位随访时间20.6个月,随访时间有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Stereotactic body radiotherapy (SBRT) is standard of care for inoperable stage I or II non-small cell lung cancer (NSCLC). KEYNOTE-867 (ClinicalTrials.gov identifier: NCT03924869) evaluated the addition of pembrolizumab to SBRT in participants diagnosed with stage I or II NSCLC that was inoperable or in participants who refused surgery. METHODS: Adults with untreated, stage I or II (T1 to limited T3, N0, M0) NSCLC (AJCC 8th edition) that was inoperable, or adults who refused surgery, were randomly assigned 1:1 to thoracic SBRT to primary tumors for ≤2 weeks concomitantly with pembrolizumab 200 mg or placebo once every 3 weeks for ≤17 cycles. The primary end point was event-free survival (EFS) by blinded independent central review. RESULTS: A total of 448 participants were randomly assigned to SBRT plus pembrolizumab (n = 227) or SBRT plus placebo (n = 221). The median time from random assignment to the data cutoff date (June 11, 2024) for the prespecified first interim analysis was 20.6 (range, 1.3-56.8) months. The median EFS (95% CI) was 31.2 (22.5 to 39.1) months and 28.3 (19.8 to 33.1) months for the pembrolizumab and placebo arms, respectively (hazard ratio, 0.92 [95% CI, 0.69 to 1.24]; P = .2932). Among participants who received ≥1 dose of study treatment, grade 3-5 treatment-related adverse events (AEs) occurred in 46/226 (20.4%) participants in the pembrolizumab arm and 8/218 (3.7%) participants in the placebo arm. There were five treatment-related deaths all of which occurred in the pembrolizumab arm (2.2%). CONCLUSION: The addition of pembrolizumab to SBRT did not improve EFS and was associated with a higher incidence of treatment-related AEs compared with SBRT alone in participants with inoperable stage I or II NSCLC. Based on the benefit-risk profile, the KEYNOTE-867 trial was prematurely stopped, and all study treatment was discontinued.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Jabbour SK, Sótér S, Eaton M, et al. KEYNOTE-867: A Phase III, Randomized, Double-Blind Study of Stereotactic Body Radiotherapy With Pembrolizumab for Unresected Stage I or II Non-Small Cell Lung Cancer. J Clin Oncol. 2026. PMID: 42950173. doi:10.1200/JCO-26-00404

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。